Alkermes plc

Valuation Analysis

About the Company

Alkermes plc en bref

Alkermes plc (ALKS) is currently trading at 39,26 € with a market capitalization of 6,5 Md €. The trailing P/E ratio stands at 49.99x, with a forward P/E of 19.11x. The 52-week range spans from 21,97 € to 39,93 €; the current price is 1.7% below the yearly high. Year-over-year revenue growth stands at +28.2%. The net profit margin stands at 9.77%.

💰 Dividende

Alkermes plc currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

16 analystes évaluent Alkermes plc (ALKS) au consensus : Acheter. L'objectif de cours moyen est de 40,25 €, soit un potentiel de +2.52% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 29,67 € à 51,49 €.

Alkermes plc : la thèse d'investissement en détail

Alkermes plc (ALKS) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in Ireland. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 28.2% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 87.45%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Le scénario baissier

Short interest sits at 14.47% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

The EV/EBITDA multiple of 30.22x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The forward P/E of 19.11x is meaningfully below the trailing 49.99x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 96.3% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (14.47%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Alkermes plc?

Compare top-rated brokers — low fees, trusted providers, fully regulated.